The Experts below are selected from a list of 33 Experts worldwide ranked by ideXlab platform
Michael Weber - One of the best experts on this subject based on the ideXlab platform.
-
efficacy and tolerability of Tasosartan a novel angiotensin ii receptor blocker results from a 10 week double blind placebo controlled dose titration study
American Heart Journal, 1999Co-Authors: Joel M Neutel, Vardaman Buckalew, Steven G Chrysant, William J Mroczek, Dennis A Ruff, Michael WeberAbstract:Abstract Background Angiotensin II receptor antagonists are selective blockers of the renin-angiotensin system and represent an alternative to angiotensin-converting enzyme inhibitors in the treatment of hypertension. Tasosartan is a newly developed nonpeptide AT 1 receptor blocker. Methods and Results In this double-blind, randomized, dose-titration, multicenter trial, Tasosartan and placebo were compared in patients with stage I and stage II hypertension. A prequalification washout period (antihypertensive medications withdrawn) and a 2-week qualification period (patients received single-blind placebo) preceded a 10-week, double-blind treatment period. The patients received either 50 mg Tasosartan ( n = 132) or placebo ( n = 130) once per day and were evaluated once per week. The dose of Tasosartan was increased at 3-week intervals to 100 mg and then to 200 mg if the mean sitting diastolic blood pressure (SiDBP) exceeded 90 mm Hg. Compared with placebo, Tasosartan produced significantly ( P P P Conclusions These results demonstrate that Tasosartan at 50 to 200 mg given once a day over a titration period of 10 weeks was effective and safe in the treatment of essential hypertension. (Am Heart J 1999;137:118-25.)
Yves Lacourciere - One of the best experts on this subject based on the ideXlab platform.
-
effects of angiotensin antagonism with Tasosartan on regional and systemic haemodynamics in hypertensive patients
Journal of Hypertension, 1998Co-Authors: Caroline Rheaume, Paulo H Waib, Yves Lacourciere, J ClerouxAbstract:Objective Evaluate the effects of 2 weeks of treatment with Tasosartan (1) on cardiac function at rest and during submaximal exercise, (2) on exercise peak oxygen uptake, and (3) on regional haemodynamics at rest in a control condition and during the recovery period of submaximal exercise in patients with essential hypertension. Design and methods Twenty-four patients with moderate hypertension participated in this randomized, double-blind, crossover, placebo-controlled study. Each patient received Tasosartan (100 mg/day) or placebo during two periods of 2 weeks separated by 2 weeks of washout Ambulatory blood pressure was assessed at the end of each period. Blood pressure, heart rate, cardiac output, stroke volume, total peripheral resistance were measured at rest and during submaximal exercise at the same end points. Regional blood flow and vascular resistance were additionally assessed in the forearm and calf at rest Results At rest in the control condition, Tasosartan significantly reduced blood pressure although total peripheral resistance, cardiac output and stroke volume as well as forearm and calf vascular resistances were not significantly affected compared to placebo. During submaximal exercise and during the recovery period after submaximal exercise, the reduced blood pressure found with Tasosartan was associated with a reduced total peripheral resistance compared to placebo whereas cardiac output, heart rate, or stroke volume were not affected. Peak workload and oxygen uptake were unaffected by Tasosartan. Conclusions The results of this study indicate that antagonism of the AT 1 receptor with Tasosartan reduces blood pressure at rest and during submaximal exercise but not during maximal exercise. The reduced blood pressure was associated with a reduced total peripheral resistance during submaximal exercise but not at rest in the control condition while cardiac output was unaltered in either condition. Lastly, Tasosartan did not impair working capacity as measured from peak workload and oxygen uptake.
-
a randomized double blind placebo controlled parallel group multicenter trial of four doses of Tasosartan in patients with essential hypertension
American Journal of Hypertension, 1998Co-Authors: Yves Lacourciere, Alan H Gradman, James L Pool, Laura P Svetkey, Pierre Larochelle, Jacques De Champlain, William B SmithAbstract:Tasosartan, a new, long-act ing, nonpeptide angiotensin II receptor antagonist was evaluated in a randomized, double-blind, placebo-controlled, multicenter trial at 21 sites in the United States and Canada. After a 2-week, placebo washout qualification period, 278 patients (187 men/91 women) with a mean age of 53.4 ± 9.5 years (range, 30 to 70 years) and a baseline sitting diastolic blood pressure (DBP) of 95 to 114 mm Hg were randomly assigned to receive placebo (n = 56), or 10 mg (n = 57), 30 mg (n = 55), 100 mg (n = 55), or 300 mg (n = 55) Tasosartan for 4 weeks. The treatment period was followed by a 2-week washout period. Ambulatory blood pressure (BP) monitoring was performed at the end of the placebo washout period and after at least 4 weeks of double-blind treatment. Clinically significant placebo-adjusted differences in baseline sitting systolic blood pressure (SBP)/DBP were observed in the 10 mg (5/3 mm Hg), 30 mg (5/4 mm Hg), 100 mg (10/7 mm Hg) and 300 mg (10/7 mm Hg) dose groups (P < .05). A dose-response relationship (P < .001) was observed within 1 to 2 weeks of treatment initiation and was maintained throughout the double-blind period. Discontinuation of Tasosartan therapy was not associated with rebound hypertension. Moreover, significant (P < .05) placebo-adjusted differences in ambulatory SBP/DBP and a significant dose-response relationship (P < .001) were observed with all Tasosartan dosages during the 24-h, daytime, and nighttime periods. Placebo-adjusted trough-to-peak ratios ranged from 87% to 100% for ambulatory SBP and 64% to 81% for DBP. In general, no significant differences were observed between the Tasosartan treatment groups and the placebo group in the incidence of adverse events. Headache incidence was significantly lower in the 300 mg dose group than the placebo group. In conclusion, Tasosartan at dosages of 10, 30, 100, or 300 mg given once daily produced a significant and dose-related reduction in both clinic and ambulatory BP that was maintained over the 24-h period. Tasosartan was generally well tolerated.
William B Smith - One of the best experts on this subject based on the ideXlab platform.
-
a randomized double blind placebo controlled parallel group multicenter trial of four doses of Tasosartan in patients with essential hypertension
American Journal of Hypertension, 1998Co-Authors: Yves Lacourciere, Alan H Gradman, James L Pool, Laura P Svetkey, Pierre Larochelle, Jacques De Champlain, William B SmithAbstract:Tasosartan, a new, long-act ing, nonpeptide angiotensin II receptor antagonist was evaluated in a randomized, double-blind, placebo-controlled, multicenter trial at 21 sites in the United States and Canada. After a 2-week, placebo washout qualification period, 278 patients (187 men/91 women) with a mean age of 53.4 ± 9.5 years (range, 30 to 70 years) and a baseline sitting diastolic blood pressure (DBP) of 95 to 114 mm Hg were randomly assigned to receive placebo (n = 56), or 10 mg (n = 57), 30 mg (n = 55), 100 mg (n = 55), or 300 mg (n = 55) Tasosartan for 4 weeks. The treatment period was followed by a 2-week washout period. Ambulatory blood pressure (BP) monitoring was performed at the end of the placebo washout period and after at least 4 weeks of double-blind treatment. Clinically significant placebo-adjusted differences in baseline sitting systolic blood pressure (SBP)/DBP were observed in the 10 mg (5/3 mm Hg), 30 mg (5/4 mm Hg), 100 mg (10/7 mm Hg) and 300 mg (10/7 mm Hg) dose groups (P < .05). A dose-response relationship (P < .001) was observed within 1 to 2 weeks of treatment initiation and was maintained throughout the double-blind period. Discontinuation of Tasosartan therapy was not associated with rebound hypertension. Moreover, significant (P < .05) placebo-adjusted differences in ambulatory SBP/DBP and a significant dose-response relationship (P < .001) were observed with all Tasosartan dosages during the 24-h, daytime, and nighttime periods. Placebo-adjusted trough-to-peak ratios ranged from 87% to 100% for ambulatory SBP and 64% to 81% for DBP. In general, no significant differences were observed between the Tasosartan treatment groups and the placebo group in the incidence of adverse events. Headache incidence was significantly lower in the 300 mg dose group than the placebo group. In conclusion, Tasosartan at dosages of 10, 30, 100, or 300 mg given once daily produced a significant and dose-related reduction in both clinic and ambulatory BP that was maintained over the 24-h period. Tasosartan was generally well tolerated.
Alan H Gradman - One of the best experts on this subject based on the ideXlab platform.
-
a randomized double blind placebo controlled parallel group multicenter trial of four doses of Tasosartan in patients with essential hypertension
American Journal of Hypertension, 1998Co-Authors: Yves Lacourciere, Alan H Gradman, James L Pool, Laura P Svetkey, Pierre Larochelle, Jacques De Champlain, William B SmithAbstract:Tasosartan, a new, long-act ing, nonpeptide angiotensin II receptor antagonist was evaluated in a randomized, double-blind, placebo-controlled, multicenter trial at 21 sites in the United States and Canada. After a 2-week, placebo washout qualification period, 278 patients (187 men/91 women) with a mean age of 53.4 ± 9.5 years (range, 30 to 70 years) and a baseline sitting diastolic blood pressure (DBP) of 95 to 114 mm Hg were randomly assigned to receive placebo (n = 56), or 10 mg (n = 57), 30 mg (n = 55), 100 mg (n = 55), or 300 mg (n = 55) Tasosartan for 4 weeks. The treatment period was followed by a 2-week washout period. Ambulatory blood pressure (BP) monitoring was performed at the end of the placebo washout period and after at least 4 weeks of double-blind treatment. Clinically significant placebo-adjusted differences in baseline sitting systolic blood pressure (SBP)/DBP were observed in the 10 mg (5/3 mm Hg), 30 mg (5/4 mm Hg), 100 mg (10/7 mm Hg) and 300 mg (10/7 mm Hg) dose groups (P < .05). A dose-response relationship (P < .001) was observed within 1 to 2 weeks of treatment initiation and was maintained throughout the double-blind period. Discontinuation of Tasosartan therapy was not associated with rebound hypertension. Moreover, significant (P < .05) placebo-adjusted differences in ambulatory SBP/DBP and a significant dose-response relationship (P < .001) were observed with all Tasosartan dosages during the 24-h, daytime, and nighttime periods. Placebo-adjusted trough-to-peak ratios ranged from 87% to 100% for ambulatory SBP and 64% to 81% for DBP. In general, no significant differences were observed between the Tasosartan treatment groups and the placebo group in the incidence of adverse events. Headache incidence was significantly lower in the 300 mg dose group than the placebo group. In conclusion, Tasosartan at dosages of 10, 30, 100, or 300 mg given once daily produced a significant and dose-related reduction in both clinic and ambulatory BP that was maintained over the 24-h period. Tasosartan was generally well tolerated.
-
tolerability profile of Tasosartan a long acting angiotensin ii at1 receptor blocker in the treatment of patients with essential hypertension
Current Therapeutic Research-clinical and Experimental, 1997Co-Authors: Suzanne Oparil, Alan H Gradman, Vasilios Papademetriou, Michael A WeberAbstract:Abstract This paper summarizes tolerability data for 1420 patients with essential hypertension who were enrolled in eight double-masked, controlled clinical trials and who received Tasosartan, a long-acting, nonpeptidic angiotensin II AT 1 receptor blocker. A total of 2084 patients were included in all treatment groups in these studies. Patients were treated with Tasosartan at doses ranging from 10 to 600 mg, over periods of 3 to 16 weeks, except for one study with a 6-day treatment period. Tasosartan was administered once daily (seven studies) or twice daily (one study). No adverse events occurred at a significantly greater frequency in Tasosartan-treated patients than in patients who received placebo. Headache, the most frequently reported adverse event, occurred significantly less frequently among Tasosartan-treated patients than among those taking placebo (19% and 28%, respectively). The following adverse events (Tasosartan and placebo groups) were reported by at least 3% of Tasosartan-treated patients: asthenia (7% in each group), pharyngitis (7% in each group), dizziness (7% and 5%, respectively), infection (6% and 7%, respectively), rhinitis (4% and 6%, respectively), pain (4% in each group), diarrhea (4% in each group), nausea (3% in each group), and dyspepsia (3% and 2%, respectively). Cough occurred with a similar frequency in the Tasosartan group and in the placebo group (2% and 3%, respectively). Peripheral edema occurred in 2.7% of Tasosartan-treated patients and 3.4% of the patients who received placebo. Hyperglycemia occurred in
Joel M Neutel - One of the best experts on this subject based on the ideXlab platform.
-
efficacy and tolerability of Tasosartan a novel angiotensin ii receptor blocker results from a 10 week double blind placebo controlled dose titration study
American Heart Journal, 1999Co-Authors: Joel M Neutel, Vardaman Buckalew, Steven G Chrysant, William J Mroczek, Dennis A Ruff, Michael WeberAbstract:Abstract Background Angiotensin II receptor antagonists are selective blockers of the renin-angiotensin system and represent an alternative to angiotensin-converting enzyme inhibitors in the treatment of hypertension. Tasosartan is a newly developed nonpeptide AT 1 receptor blocker. Methods and Results In this double-blind, randomized, dose-titration, multicenter trial, Tasosartan and placebo were compared in patients with stage I and stage II hypertension. A prequalification washout period (antihypertensive medications withdrawn) and a 2-week qualification period (patients received single-blind placebo) preceded a 10-week, double-blind treatment period. The patients received either 50 mg Tasosartan ( n = 132) or placebo ( n = 130) once per day and were evaluated once per week. The dose of Tasosartan was increased at 3-week intervals to 100 mg and then to 200 mg if the mean sitting diastolic blood pressure (SiDBP) exceeded 90 mm Hg. Compared with placebo, Tasosartan produced significantly ( P P P Conclusions These results demonstrate that Tasosartan at 50 to 200 mg given once a day over a titration period of 10 weeks was effective and safe in the treatment of essential hypertension. (Am Heart J 1999;137:118-25.)
